Latest Breaking News On - லூயிஸ் வாஷிங்டன் பல்கலைக்கழகம் - Page 5 : comparemela.com

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023 Conference Call Today at 4:30 p.m. (ET) News provided by Share this article Share this article ROCKVILLE, Md., May 5, 2021 /PRNewswire/  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2021.

United statesStevena shallcrossCompany phaseWashington university school of medicineNet loss attributable to synthetic biologics incWashington universitySafety monitoring committeeLouis washington universitySynthetic biologics incClinical developmentSynthetic biologicsChief executive officerWashington university schoolMassachusetts general hospitalEnded marchSynthetic biologic